

Limited Liability Company ("naamloze vennootschap") Registered Office: Generaal de Wittelaan 11B, 2800 Mechelen, Belgium Company Number VAT BE 0505.640.808 RLP Antwerp, division Mechelen

## **VOTE BY MAIL FORM**

## SPECIAL SHAREHOLDERS' MEETING

to be held on Friday 27 September 2019 at 10 a.m. CEST

This is an unofficial English translation, for information purposes only.

Please only sign and return the original Dutch version.

This form should be used by holders of shares of Biocartis Group NV (the "Company") who want to vote by mail.

The vote by mail form must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, or an electronic signature that complies with the conditions set out in Article 1322 of the Belgian Civil Code.

The signed and completed form must reach the Company at the latest on the sixth calendar day prior to the special shareholders' meeting, i.e. on or before Saturday 21 September 2019 at the latest. Forms sent to the Company must be sent by mail to:

Biocartis Group NV Attention: Tim Vandorpe Corporate Counsel Generaal de Wittelaan 11B 2800 Mechelen Belgium

or by e-mail to:

legal@biocartis.com

Holders of shares of the Company who wish to vote by mail must also register for the special shareholders' meeting, as described in the notice convening the special shareholders' meeting. Holders of dematerialized shares must attach to the present form a certificate issued by the applicable settlement institution for the shares concerned, or by a certified account holder, confirming the number of shares that have been registered in their name on the registration date (i.e. Friday 13 September 2019, at midnight (12:00 a.m., Central European Summer Time)) with which they want to participate to the special shareholders' meeting.

In case of amendments to the agenda or if new draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions. This will be done no later than on the fifteenth calendar day prior to the special shareholders' meeting, i.e. on or before Thursday 12 September 2019 at the latest. At that time, the Company will also make available amended forms for votes by mail. Votes by mail that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the votes by mail apply, subject, however, to applicable law and the further clarifications set out in this form. In accordance with the Belgian Companies Code, a

vote via vote by mail for an agenda item in relation to which a new proposed resolution has been submitted by one or more shareholders holding at least 3% of the share capital, is invalid.

The undersigned (the	e "Undersigned")				
First Name: Family Name: Address:					
Corporate name: Corporate form: Registered office:					
Represented by (first name, family name and capacity):		ssued by Biocartis Group NV, with its registered office at Generaal			
	300 Mechelen, Belgium:		y blocards Group IVV, wi	  - 	nice at Generaai
	Form of the above r (please tick the appro)  Registered  Dematerialized				

Hereby irrevocably votes, as indicated hereafter in the appropriate boxes, on the items of the following agenda:

## SPECIAL SHAREHOLDERS' MEETING

**Agenda and proposed resolution:** The agenda and proposed resolution of the special shareholders' meeting of the Company, which, as the case may be, can be amended at the meeting on behalf of the Board of Directors, are as follows:

## 1. Approval in accordance with Article 556 of the Belgian Companies Code

*Background:* On 9 May 2019, the Company issued convertible bonds for a total principal amount of EUR 150 million. The terms and conditions of the convertible bonds can be consulted on the

website of the Company. Conditions 5(b)(x) and 6(d) of the convertible bonds provide that, if a change of control over the Company occurs, the conversion price of the convertible bonds will be adjusted in proportion to the already elapsed time since the closing date (i.e. 9 May 2019) and the bondholders may request the early redemption of their convertible bonds at their principal amount, together with the accrued and unpaid interests. For more information on the issuance of the convertible bonds, reference is made to the report of the board of directors of the Company drawn up in accordance with Articles 583 and 596 of the Belgian Companies Code (*Wetboek van vennootschappen*) of 7 May 1999, as amended or superseded, which can be consulted on the website of the Company.

Proposed resolution: The general meeting of shareholders takes note of, approves and ratifies in accordance with Article 556 of the Belgian Companies Code (Wetboek van vennootschappen) of 7 May 1999, as amended or superseded (the "BCC"), all clauses in the terms and conditions (the "Conditions") of the convertible bonds, issued by the Company on 9 May 2019, maturing on 9 May 2024 (ISIN BE0002651322), which come into effect at the moment a change of control occurs, including, but not limited to, Conditions 5(b)(x) and 6(d) and which fall or could be considered to fall within the scope of Article 556 BCC relating to the granting of rights to third parties that affect the assets of the Company, or create a debt or a liability for which the Company is liable, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it. The general meeting of shareholders also grants a special power of attorney to each director of the Company and to Mr. Tim Vandorpe (corporate counsel) (each a "Proxy Holder"), each Proxy Holder acting individually and with the right of substitution, to complete the formalities required by Article 556 BCC with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

Voting instruction:

☐ I AGREE	☐ I DO NOT AGREE	☐ ABSTENTION
	ale ale	

The aforementioned votes apply to the special shareholders' meeting that will be held on 27 September 2019. In case the aforementioned special shareholders' meeting would be postponed or suspended, the aforementioned votes will also apply to the general meeting that would be held having the same agenda, as relevant:

☐ Yes

□ No

Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the Undersigned shall be deemed to have selected "Yes". Please note that in order to apply for such subsequent meeting, holders of shares must again register for such meeting.

In case of amendments during the meeting to a proposed resolution or in case of a new proposed resolution during the meeting:1

- the Undersigned votes for the amended or new resolution
- □ the Undersigned votes against the amended or new resolution
- the Undersigned abstains from the vote on the amended or new resolution

	the following person is appointed as special proxy holder, with power of substitution, to vote in the name of the Undersigned on the amended or new resolution: Mr./Mrs
	<sup>1</sup> Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended proposed resolution or new proposed resolution.
	<sup>2</sup> In case the Chairman of the Board of Directors of the Company is appointed as special proxy holder, the Chairman (or, as the case may be, another Director, employee or agent of the Company appointed as substitute of the Chairman pursuant to a sub delegation if the Chairman is hindered to participate in the general shareholders' meeting) will in such event vote on the amended proposed resolutions or new proposed resolutions in the manner as will be supported or recommended by the Board of Directors. Please note that the Chairman of the Board of Directors of the Company (or, as the case may be, the substitute of the Chairman) is a director, employee or agent of Biocartis Group NV and therefore has a potential conflict of interest as provided for in Article 547bis, §4 BCC.
_	r shall also serve as notification within the meaning of Article 536, §2, par. 3 BCC with ecial shareholders' meeting of the Company to be held on 27 September 2019.
Done at	2019

Signature.....